Form D · Biotechnology
32 Biosciences, Inc.
Illinois, IL · CIK 0002020332
Offering snapshot reported May 31, 2024 · SEC filing
- Reported sold
- $160K Offering amount: $6M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 21, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 31, 2024 | Initial | $160,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-514856
Source: Form D, filed May 31, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John C. Alverdy | Director |
| Eugene Chang | Director |
| Jaime Contreras | Director |
| Peter Farmakis | Director, Executive |
| Joseph Francis Pierre | Director |
| Brian Yoor | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3333 Green Bay Rd Suite 210
Illinois, IL, 60064
Illinois, IL, 60064